Abstract
Potential inhibitory effects of the antiangiogenic drug TNP-470 on rat urinary bladder carcinogenesis were investigated in F344 male rats initiated with 0.05% BBN in the drinking water for 8 weeks. Group 1 was then continuously treated with TNP-470 by subcutaneous injection using osmotic minipump until the end of the experiment; group 2 served as the control with only initiation. The incidences and multiplicities of papillomas and carcinomas in the TNP-470-treated group were significantly decreased compared to the control group values along with the tumor vascular density. In conclusion, TNP-470 can inhibit rat urinary bladder carcinogenesis, presumably through its effects on angiogenesis.
Publication types
-
Comparative Study
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Angiogenesis Inhibitors / pharmacology*
-
Animals
-
Biopsy, Needle
-
Blotting, Northern
-
Butylhydroxybutylnitrosamine
-
Chi-Square Distribution
-
Cyclohexanes
-
Dose-Response Relationship, Drug
-
Drug Administration Schedule
-
Immunohistochemistry
-
Male
-
Neoplasms, Experimental
-
Neovascularization, Pathologic / prevention & control*
-
O-(Chloroacetylcarbamoyl)fumagillol
-
Probability
-
RNA, Messenger / analysis
-
Random Allocation
-
Rats
-
Rats, Inbred F344
-
Sensitivity and Specificity
-
Sesquiterpenes / pharmacology*
-
Urinary Bladder Neoplasms / drug therapy*
-
Urinary Bladder Neoplasms / pathology*
-
Vascular Endothelial Growth Factor A / analysis
Substances
-
Angiogenesis Inhibitors
-
Cyclohexanes
-
RNA, Messenger
-
Sesquiterpenes
-
Vascular Endothelial Growth Factor A
-
Butylhydroxybutylnitrosamine
-
O-(Chloroacetylcarbamoyl)fumagillol